Comparison of ovarian stimulation regimens for in vitro fertilization (IVF) with and without a gonadotropin-releasing hormone (GnRH) agonist: Results of a randomized study
- 1 December 1990
- journal article
- clinical trial
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 7 (6) , 358-362
- https://doi.org/10.1007/bf01130591
Abstract
In order to diminish the cancellation rate due to a premature endogeneous LH surge and/or to a poor ovarian response and thus increasing the pregnancy rate, a GnRH agonist (Buserelin) was applied in patients starting their first ovarian stimulation with gonadotropins for IVF. All patients suffered from tubal infertility and were not older than 40 years. Each woman was allocated randomly to one of three groups: the conventional treatment with hMG alone (group I), patients from group II started the hMG treatment shortly after the LH rise caused by the GnRH agonist and patients in group III commenced the hMG treatment when an hypogonadotropic state was achieved after a long treatment of Buserelin. All male partners had a normal spermiogram. A reduction of poor responders to the superovulation is seen in the short-term group (6%), compared with the other two groups (14%). In some cases from group III ovarian cyst formation led to the cancellation of the treatment. The long-term group differs significantly from the other two in the duration of the gonadotropin stimulation and the number of ampoules hMG used. A severe ovarian overstimulation syndrome was not observed. There is no difference in the number of retrieved oocytes and the fertilization rate among the three groups. The pregnancy rate per cycle or per patients in the group with a short-term GnRH-agonist regimen is significantly higher compared to that of the group using the conventional hMG treatment.Keywords
This publication has 24 references indexed in Scilit:
- Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilizationFertility and Sterility, 1989
- Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropinsFertility and Sterility, 1989
- Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapyFertility and Sterility, 1989
- Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization programFertility and Sterility, 1988
- An alternate approach to controlled ovarian hyperstimulation in “poor responders”: pretreatment with a gonadotropin-releasing hormone analogFertility and Sterility, 1988
- Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrievalFertility and Sterility, 1987
- Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phaseBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- INDUCTION OF OVULATION FOR IN-VITRO FERTILISATION USING BUSERELIN AND GONADOTROPINSThe Lancet, 1984
- A new systematic treatment for infertile women with abnormal hormone profilesBJOG: An International Journal of Obstetrics and Gynaecology, 1982
- Disparate Effects of Human Chorionic Gonadotropin during the Late Follicular Phase in Monkeys: Normal Ovulation, Follicular Atresia, Ovarian Acyclicity, and Hypersecretion of Follicle-Stimulating HormoneFertility and Sterility, 1980